Literature DB >> 15025615

The analgesic effect of intravenous ketamine and lidocaine on pain after spinal cord injury.

A Kvarnström1, R Karlsten, H Quiding, T Gordh.   

Abstract

BACKGROUND: Pain following spinal cord injury (SCI) is a therapeutic challenge. Only a few treatments have been assessed in randomized, controlled trials. The primary objective of the present study was to examine the analgesic effect of ketamine and lidocaine in a group of patients with neuropathic pain below the level of spinal cord injury. We also wanted to assess sensory abnormalities to see if this could help us to identify responders and if treatments resulted in changes of sensibility.
METHODS: Ten patients with spinal cord injury and neuropathic pain below the level of injury were included. The analgesic effect of ketamine 0.4 mg kg(-1) and lidocaine 2.5 mg kg(-1) was investigated. Saline was used as placebo. The drugs were infused over 40 min. A randomized, double-blind, three-period, three-treatment, cross-over design was used. Systemic plasma concentrations of ketamine and lidocaine were assessed. Pain rating was performed using a visual analogue scale (VAS). Sensory function was assessed with a combination of traditional sensory tests and quantitative measurement of temperature thresholds.
RESULTS: Response to treatment, defined as 50% reduction in VAS-score during infusion, was recorded in 5/10 in the ketamine, 1/10 in the lidocaine and 0/10 in the placebo groups. Neither ketamine nor lidocaine changed temperature thresholds or assessments of mechanical; dynamic and static sensibility. Nor could these sensory assessments predict response to treatment in this setting. Lidocaine and particularly ketamine were associated with frequent side-effects.
CONCLUSION: Ketamine but not lidocaine showed a significant analgesic effect in patients with neuropathic pain after spinal cord injury. The pain relief was not associated with altered temperature thresholds or other changes of sensory function.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15025615     DOI: 10.1111/j.1399-6576.2003.00330.x

Source DB:  PubMed          Journal:  Acta Anaesthesiol Scand        ISSN: 0001-5172            Impact factor:   2.105


  29 in total

Review 1.  Evidence-based guideline for neuropathic pain interventional treatments: spinal cord stimulation, intravenous infusions, epidural injections and nerve blocks.

Authors:  Angela Mailis; Paul Taenzer
Journal:  Pain Res Manag       Date:  2012 May-Jun       Impact factor: 3.037

2.  Early acute management in adults with spinal cord injury: a clinical practice guideline for health-care professionals.

Authors: 
Journal:  J Spinal Cord Med       Date:  2008       Impact factor: 1.985

3.  Combinations of intrathecal gamma-amino-butyrate receptor agonists and N-methyl-d-aspartate receptor antagonists in rats with neuropathic spinal cord injury pain.

Authors:  Aldric Hama; Jacqueline Sagen
Journal:  Eur J Pharmacol       Date:  2012-03-16       Impact factor: 4.432

Review 4.  A systematic review of pharmacologic treatments of pain after spinal cord injury.

Authors:  Robert W Teasell; Swati Mehta; Jo-Anne L Aubut; Brianne Foulon; Dalton L Wolfe; Jane T C Hsieh; Andrea F Townson; Christine Short
Journal:  Arch Phys Med Rehabil       Date:  2010-05       Impact factor: 3.966

5.  Central Neuropathic Pain in Spinal Cord Injury.

Authors:  Sujin Lee; Xing Zhao; Maya Hatch; Sophia Chun; Eric Chang
Journal:  Crit Rev Phys Rehabil Med       Date:  2013

Review 6.  Chronic complications of spinal cord injury.

Authors:  Nebahat Sezer; Selami Akkuş; Fatma Gülçin Uğurlu
Journal:  World J Orthop       Date:  2015-01-18

Review 7.  [Pain in patients with paraplegia].

Authors:  G Landmann; E-C Chang; W Dumat; A Lutz; R Müller; A Scheel-Sailer; K Schwerzmann; N Sigajew; A Ljutow
Journal:  Schmerz       Date:  2017-10       Impact factor: 1.107

Review 8.  Socioeconomic position and inflammatory and immune biomarkers of cardiovascular disease: applications to the Panel Study of Income Dynamics.

Authors:  Allison E Aiello; George A Kaplan
Journal:  Biodemography Soc Biol       Date:  2009

9.  CYP2B6*6 allele and age substantially reduce steady-state ketamine clearance in chronic pain patients: impact on adverse effects.

Authors:  Yibai Li; Kate A Jackson; Barry Slon; Janet R Hardy; Michael Franco; Leeroy William; Peter Poon; Janet K Coller; Mark R Hutchinson; David C Currow; Andrew A Somogyi
Journal:  Br J Clin Pharmacol       Date:  2015-06-01       Impact factor: 4.335

Review 10.  Pharmacological management of neuropathic pain following spinal cord injury.

Authors:  Cathrine Baastrup; Nanna B Finnerup
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.